BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy the Dip on This Biotech Stock After Recent Fall
BridgeBio Pharma Inc (NASDAQ:BBIO) stock pulled back sharply from its Jan. 22 record high of $81.33, marking a three-month low after Pfizer withdrew a tafamidis patent in the European Union (EU).
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains?
BridgeBio Pharma (BBIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection
I initiate BridgeBio with a Neutral rating and a $74 target price, reflecting balanced opportunity and risk. ATTR-CM launch of Attruby reduces binary risk, but commercial sustainability and pricing durability remain uncertain amid competitive pressures. Pipeline assets like encaleret and BBP-418 offer optionality but lack near-term cash flow and face regulatory hurdles.
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
BridgeBio Has More Room To Run
BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 and infigratinib. I expect 2026 to be another strong year with Attruby U.S. net sales in the $900-950 million range and I expect BridgeBio will reach non-GAAP profitability in Q4 2026. Infigratinib's phase 3 results are expected in the following weeks and represent the next important catalyst for the company.
Biotech Stock Could Turn 4-Year Peak Into Records
BridgeBio Pharma Inc (NASDAQ:BBIO) stock is up 3.3% to trade at $70.36 at last check, and earlier hit a fresh four-year high $70.60 on a bounce off its 20-day moving average.
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript
BridgeBio Pharma, Inc. ( BBIO ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wade Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma.
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. ( BBIO ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Chinmay Shukla Neil Kumar - Co-Founder, CEO & Director Matthew Outten - Chief Commercial Officer Thomas Trimarchi - CFO & President Conference Call Participants Salim Syed - Mizuho Securities USA LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Biren Amin - Piper Sandler & Co., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Lin Tsai - Jefferies LLC, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Jason Zemansky - BofA Securities, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Trevor Allred - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon. I will be your conference operator today.
BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Ananth Sridhar - Chief Operating Officer Chinmay Shukla - VP IR & Strategic Finance Christine Siu - Chief Operating Officer in Residence Justin To - Chief Operating Officer, Skeletal Dysplasias and Gene Therapy Matthew Outten - Chief Commercial Officer Neil Kumar - Co-Founder, CEO & Director Thomas Trimarchi - CFO & President Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Biren N. Amin - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Gregory Allen Harrison - Scotiabank Global Banking and Markets, Research Division Lin Tsai - Jefferies LLC, Research Division Mani Foroohar - Leerink Partners LLC, Research Division Paul Choi - Goldman Sachs Group, Inc., Research Division Salim Qader Syed - Mizuho Securities USA LLC, Research Division Tyler Martin Van Buren - TD Cowen, Research Division Operator Good afternoon.
